e-ISSN: 2746-5152

Eureka Herba Indonesia

[EHI]

https://eurekabiomedical.com

Bay Leaf Extract as a Potential Therapeutic Agent for LDL Reduction in Hypercholesterolemia: A Dose-Response Study

Kadek Adi Sudarmika[1*], Putu Oky Ari Tania[2]

[1]Faculty of Medicine, Universitas Wijaya Kusuma, Surabaya, Indonesia

[2]Biomedical Section of Biomolecular Research, Faculty of Medicine, Universitas Wijaya Kusuma, Surabaya, Indonesia

ARTICLE INFO

Keywords:
Bay leaf extract
Cardiovascular disease
Dose-response
Hypercholesterolemia
LDL cholesterol

***Corresponding author:**
Kadek Adi Sudarmika

E-mail address:
adisudarmika21@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/ehi.v5i3.126

A B S T R A C T

Hypercholesterolemia, characterized by elevated low-density lipoprotein (LDL) cholesterol levels, is a major risk factor for cardiovascular disease. The current study investigated the dose-dependent effects of bay leaf extract on LDL cholesterol reduction in a hypercholesterolemic rat model. Male Wistar rats were fed a high-fat diet to induce hypercholesterolemia. They were then randomly assigned to five groups: positive control (simvastatin), negative control (standard diet), and three treatment groups receiving graded doses of bay leaf extract (0.72 g, 1.08 g, and 1.80 g). LDL cholesterol levels were measured after seven days of treatment. Bay leaf extract administration resulted in a dose-dependent reduction in LDL cholesterol levels. The highest dose (1.80 g) exhibited comparable efficacy to simvastatin in lowering LDL cholesterol. In conclusion, bay leaf extract demonstrates potential as a therapeutic agent for managing hypercholesterolemia by effectively reducing LDL cholesterol levels. The optimal dose for LDL reduction appears to be 1.80 g. Further research is warranted to explore the underlying mechanisms and clinical implications of these findings.

1. Introduction

Cardiovascular diseases (CVDs) have persistently cast a long shadow over global health, representing the leading cause of mortality worldwide. The World Health Organization's 2019 report paints a stark picture, revealing that CVDs claimed an estimated 17.9 million lives, accounting for a staggering 32% of all deaths globally. The primary culprits within this grim statistic are heart attacks and strokes, responsible for 85% of these fatalities. The burden of CVDs extends beyond mortality, inflicting substantial morbidity and economic costs on societies worldwide. The insidious nature of CVDs often involves a protracted period of asymptomatic progression, leading to delayed diagnosis and treatment, further exacerbating their impact. At the heart of the CVD epidemic lies hypercholesterolemia, a condition characterized by abnormally high levels of cholesterol in the blood. Cholesterol, a waxy, fat-like substance, plays a crucial role in various physiological processes, including cell membrane structure, hormone synthesis, and vitamin D production. However, an excess of cholesterol, particularly low-density lipoprotein (LDL) cholesterol, poses a significant threat to cardiovascular health. LDL cholesterol, often referred to as "bad" cholesterol, is prone to oxidation and deposition in arterial walls, initiating the atherosclerotic process. The gradual accumulation of cholesterol-laden plaques within the arteries leads to their narrowing and hardening, impeding blood flow and increasing the risk of heart attacks, strokes, and other cardiovascular events.[1-3]

The association between hypercholesterolemia and CVDs is well-established, with numerous studies

demonstrating a strong correlation between elevated LDL cholesterol levels and increased cardiovascular risk. The atherosclerotic process triggered by LDL cholesterol deposition is a complex interplay of inflammation, oxidative stress, and endothelial dysfunction. The resulting plaques not only obstruct blood flow but also create a vulnerable environment prone to rupture, leading to the formation of blood clots that can further occlude arteries and precipitate acute cardiovascular events. The current mainstay of hypercholesterolemia management is statin therapy. Statins, a class of drugs that inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, have proven efficacy in reducing LDL cholesterol levels and mitigating cardiovascular risk. However, their use is often accompanied by a spectrum of adverse effects, ranging from muscle pain and weakness to liver damage and an increased risk of type 2 diabetes. These side effects can significantly impact patient adherence and quality of life, underscoring the need for alternative therapeutic approaches. The limitations of statin therapy extend beyond their adverse effects. A subset of patients exhibits statin intolerance, experiencing debilitating side effects even at low doses, precluding their use. Furthermore, statins may not achieve sufficient LDL cholesterol reduction in some individuals, necessitating the exploration of adjunctive or alternative therapies. The quest for safer and more effective strategies for managing hypercholesterolemia has fueled research into natural products, particularly those derived from plants, with a rich history of traditional use in various cultures.[4,5]

Natural products, particularly those derived from plants, have long been recognized for their potential in disease prevention and treatment. The use of plants for medicinal purposes dates back centuries, with traditional medicine systems across the globe relying on their therapeutic properties. The vast array of bioactive compounds present in plants, including alkaloids, flavonoids, terpenoids, and polyphenols, offers a treasure trove of potential therapeutic agents. These compounds exhibit a wide range of biological activities, including antioxidant, anti-inflammatory, anti-microbial, and hypolipidemic effects. Among the myriad of plants with purported health benefits, bay leaf (*Eugenia polyantha* Wight) has emerged as a promising candidate for hypercholesterolemia management. Bay leaf, a widely used culinary herb, boasts a rich history of traditional use in various cultures for its medicinal properties. Recent scientific investigations have corroborated these traditional claims, demonstrating the cholesterol-lowering effects of bay leaf extract in both animal and human studies. The hypolipidemic activity of bay leaf extract is attributed to its bioactive constituents, including flavonoids and tannins. Flavonoids, a diverse group of polyphenolic compounds, are potent antioxidants that scavenge free radicals and protect against oxidative stress. In addition to their antioxidant properties, flavonoids have been shown to inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This inhibition reduces cholesterol production in the liver, leading to lower circulating LDL levels. Tannins, another class of bioactive compounds found in bay leaf extract, exert their hypolipidemic effects by impeding intestinal fat absorption. Tannins bind to dietary cholesterol, preventing its uptake into the bloodstream and promoting its excretion.[6,7] While the cholesterol-lowering potential of bay leaf extract has been established, the optimal dose for achieving maximal LDL cholesterol reduction remains to be elucidated. Understanding the dose-response relationship is crucial for determining the most effective and safe dosage regimen for therapeutic use. The present study aims to address this knowledge gap by investigating the dose-dependent effects of bay leaf extract on LDL cholesterol levels in a hypercholesterolemia rat model.

2. Methods

The present investigation employed a true experimental framework, utilizing a completely randomized design to ensure unbiased allocation of subjects and minimize confounding variables. This rigorous approach aimed to establish a clear cause-and-effect relationship between the administration of bay leaf extract and its impact on LDL cholesterol

levels in a hypercholesterolemic rat model. The study was conducted in adherence to ethical guidelines and received approval from the Wijaya Kusuma Surabaya University Health Research Ethics Commission (approval number: 10109/SLE/FK/UWKS/2016). The study population comprised male Wistar rats, a strain widely employed in biomedical research due to its physiological similarities to humans and well-characterized responses to dietary interventions. The selection of male rats aimed to eliminate potential hormonal influences associated with female reproductive cycles, thereby enhancing the internal validity of the study. The rats were carefully chosen based on specific criteria, including age (11-12 weeks) and body weight (150-200 grams), to ensure a homogenous sample and minimize inter-individual variability. The animals were procured from a reputable supplier and housed in the Experimental Animal Laboratory of the Faculty of Medicine, Wijaya Kusuma University Surabaya. The laboratory environment was meticulously maintained to provide optimal conditions for the rats, including controlled temperature, humidity, and light cycles. The rats were housed in spacious cages with ample bedding and provided ad libitum access to water throughout the study duration.

The induction of hypercholesterolemia, a state characterized by elevated blood cholesterol levels, was achieved through a dietary intervention. The rats were fed a high-fat diet for a period of 12 days. The composition of the high-fat diet was carefully formulated to promote hypercholesterolemia, with a higher proportion of fat compared to a standard rodent diet. The diet consisted of a mixture of fish meal, soybeans, rice bran, rice, corn, wheat flour, minerals, fat, molasses, and multivitamins. The precise proportions of these ingredients were meticulously adjusted to ensure a consistent and reproducible induction of hypercholesterolemia across all experimental subjects. The high-fat diet was administered daily at a fixed quantity of 20 grams per rat, ensuring adequate caloric intake while promoting the desired elevation in cholesterol levels. The bay leaf extract used in this study was prepared through a meticulous extraction process to ensure the preservation of its bioactive constituents. Dried bay leaves were subjected to maceration, a technique involving soaking the plant material in a solvent (70% ethanol) to facilitate the extraction of soluble compounds. The maceration process was conducted over a period of five days, allowing for thorough extraction of the desired phytochemicals. The resulting filtrate, containing the extracted compounds, was then subjected to evaporation to remove the solvent and obtain a concentrated bay leaf extract. The concentrated extract was subsequently suspended in 1% carboxymethylcellulose (CMC), a viscosity-enhancing agent that facilitated oral administration to the rats. The preparation of the bay leaf extract was carried out in a controlled laboratory environment to minimize contamination and ensure the quality and consistency of the final product.

Following the induction of hypercholesterolemia, the rats were randomly assigned to five distinct experimental groups, each comprising six individuals. This randomization process aimed to distribute any potential confounding factors equally across the groups, thereby enhancing the internal validity of the study. The five groups were as follows: Positive Control (PC): This group served as a reference point for the efficacy of a known cholesterol-lowering agent. The rats in this group received a daily dose of simvastatin (0.72 mg) via oral gavage. Simvastatin, a widely prescribed statin medication, acts by inhibiting HMG-CoA reductase, a key enzyme in cholesterol biosynthesis; Negative Control (NC): This group served as a baseline for comparison, representing the natural progression of hypercholesterolemia in the absence of any intervention. The rats in this group were fed a standard diet and received 1% CMC via oral gavage, ensuring that any observed effects in the treatment groups could be attributed solely to the bay leaf extract; Treatment 1 (T1): This group received a low dose of bay leaf extract (0.72 g/day) via oral gavage. This dose was selected based on previous studies suggesting its potential efficacy in reducing cholesterol

levels; Treatment 2 (T2): This group received a moderate dose of bay leaf extract (1.08 g/day) via oral gavage. This dose represented an intermediate level between the low and high doses, allowing for the assessment of dose-dependent effects; Treatment 3 (T3): This group received a high dose of bay leaf extract (1.80 g/day) via oral gavage. This dose was selected to explore the upper limits of the therapeutic potential of bay leaf extract. The treatment period spanned seven days, during which the rats in each group received their respective treatments via oral gavage. This method ensured accurate and consistent dosing, minimizing variability in drug delivery.

Upon completion of the treatment period, the rats were humanely euthanized using chloroform anesthesia. Blood samples were then collected via cardiac puncture, a technique involving the insertion of a needle into the heart to withdraw blood. The collected blood samples were carefully labeled according to their respective groups and promptly transported to the Biochemistry Laboratory of the Faculty of Medicine, Wijaya Kusuma University Surabaya for further analysis. In the laboratory, the blood samples were centrifuged at 3000 rpm for 15 minutes to separate the serum from the cellular components. The serum, the clear liquid portion of the blood, contains various biomolecules, including cholesterol. The LDL cholesterol levels in the serum samples were then measured using the CHOD-PAP method. This enzymatic assay utilizes cholesterol oxidase to convert cholesterol to cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide subsequently reacts with 4-aminoantipyrine and phenol in the presence of peroxidase to produce a colored quinoneimine dye. The intensity of the color, measured spectrophotometrically, is directly proportional to the concentration of LDL cholesterol in the sample.

The data collected from the LDL cholesterol measurements were subjected to rigorous statistical analysis to assess the significance of any observed differences between the experimental groups. The analysis was performed using IBM SPSS Statistics for Windows, version 25.0, a powerful statistical software package widely used in biomedical research. The initial step in the analysis involved assessing the normality of the data distribution using the Kolmogorov-Smirnov test. This test compares the observed data distribution to a theoretical normal distribution and determines whether the data significantly deviates from normality. If the data were found to be normally distributed, parametric statistical tests would be employed. However, if the data deviated significantly from normality, non-parametric tests would be utilized. Following the normality assessment, Levene's test was conducted to evaluate the homogeneity of variance across the groups. This test assesses whether the variances of the different groups are equal, an assumption underlying many parametric statistical tests. If the variances were found to be homogenous, parametric tests could be confidently applied. However, if the variances were significantly different, non-parametric tests would be more appropriate. The primary analysis involved comparing the LDL cholesterol levels between the different experimental groups using the Kruskal-Wallis test. This non-parametric test is analogous to the one-way analysis of variance (ANOVA) and is used to compare the medians of multiple groups. If the Kruskal-Wallis test revealed a significant difference between the groups, post hoc analysis was performed using the Mann-Whitney U test. This non-parametric test is used to compare the medians of two independent groups and determine whether they differ significantly. The results of the statistical analysis were interpreted based on the p-value, a measure of the probability of obtaining the observed results by chance if the null hypothesis (no difference between groups) were true. A p-value less than 0.05 was considered statistically significant, indicating a low probability of the observed results occurring by chance and suggesting a true difference between the groups.

The present study was conducted in strict adherence to ethical guidelines for animal research. The study protocol was reviewed and approved by the Wijaya Kusuma Surabaya University Health Research

Ethics Commission, ensuring that all animal handling and experimental procedures were conducted in a humane and ethical manner. The rats were housed in a comfortable and enriching environment, with ample space, bedding, and access to food and water. All efforts were made to minimize any potential pain or distress experienced by the animals. The use of chloroform anesthesia for euthanasia ensured a rapid and painless death. The researchers involved in the study were trained in animal handling and experimental techniques, and all procedures were performed with utmost care and respect for the animals.

3. Results and Discussion

Figure 1 provides a clear visual representation of the changes in LDL cholesterol levels in rats before and after the administration of a high-fat diet. The primary objective of this figure is to demonstrate the successful induction of hypercholesterolemia, a condition characterized by elevated LDL cholesterol levels, in the experimental animals. The "Before Induction" bars show that all five groups (Positive Control, Negative Control, and Treatment 1-3) started with relatively low LDL cholesterol levels, ranging from approximately 14 to 16 mg/dL. This suggests that the rats were initially normocholesterolemic, providing a suitable baseline for comparison. The "After Induction" bars reveal a dramatic increase in LDL cholesterol levels across all groups. The mean LDL levels post-induction range from approximately 59 to 63 mg/dL, significantly exceeding the normal range for rats (7-27.2 mg/dL). This substantial elevation in LDL cholesterol confirms the effectiveness of the high-fat diet in inducing hypercholesterolemia. The figure demonstrates a consistent increase in LDL levels across all experimental groups, including the positive and negative controls. This consistency suggests that the high-fat diet intervention was uniformly effective in inducing hypercholesterolemia, minimizing the potential for confounding factors related to individual variability or group differences. The figure1 effectively illustrates the successful induction of hypercholesterolemia in the rats through the administration of a high-fat diet. The marked elevation in LDL cholesterol levels across all groups provides a robust foundation for the subsequent investigation into the potential LDL-lowering effects of bay leaf extract. The consistent induction of hypercholesterolemia across groups strengthens the internal validity of the study, ensuring that any observed effects in the treatment groups can be confidently attributed to the bay leaf extract intervention.



Figure 1. Effectiveness of hypercholesterolemia induction.

Table 1 showcases the mean LDL cholesterol levels and their standard deviations in different experimental groups after the treatment period. The Negative Control (NC) group, which received the standard diet without any intervention, exhibits the highest mean LDL cholesterol level (40.3 mg/dL). This serves as a baseline, highlighting the persistent hypercholesterolemic state in the absence of treatment. The positive control (PC) group, treated with simvastatin, shows a substantial reduction in LDL cholesterol (24.5 mg/dL) compared to the NC group. This confirms the well-established efficacy of simvastatin as a lipid-lowering agent. The bay leaf extract treatment groups (T1, T2, T3), which received varying doses of bay leaf extract, all demonstrate a decrease in LDL cholesterol levels compared to the NC group. The reduction is dose-dependent, with: The T1 group (0.72 g/day) showing a moderate decrease (32.1 mg/dL); The T2 group (1.08 g/day) exhibiting a further reduction (28.7 mg/dL); The T3 group (1.80 g/day) demonstrating the most significant decrease (23.9 mg/dL), reaching levels comparable to the PC group. This suggests that bay leaf extract has potent cholesterol-lowering effects, and its efficacy increases with dosage. The standard deviation values provide insight into the variability of LDL cholesterol levels within each group. The relatively small standard deviations indicate that the data points within each group are clustered close to the mean, suggesting a degree of consistency in the response to the treatments. Table 1 effectively quantifies the dose-dependent LDL cholesterol-lowering effects of bay leaf extract. The results support the potential of bay leaf extract as a natural alternative or adjunct to conventional lipid-lowering medications for managing hypercholesterolemia. The comparable efficacy of the highest dose (T3) to simvastatin further strengthens this notion.

Table 1. Effect of bay leaf extract on LDL cholesterol levels.

Group	Mean LDL cholesterol (mg/dL)	Standard deviation
PC (Simvastatin)	24.5	3.2
NC (Standard Diet)	40.3	4.1
T1 (0.72 g/day)	32.1	3.5
T2 (1.08 g/day)	28.7	3.8
T3 (1.80 g/day)	23.9	2.7

Table 2 presents the results of the post hoc analysis using the Mann-Whitney U test, which was conducted to identify specific group differences in LDL cholesterol levels after the interventions. The p-values in the table indicate the statistical significance of the differences observed between the groups being compared. The negative control group (NC) exhibited significantly higher LDL levels compared to all three treatment groups (T1, T2, and T3), as evidenced by the p-values of 0.018, 0.013, and 0.018, respectively. This suggests that all doses of bay leaf extract were effective in reducing LDL cholesterol compared to no treatment. The highest dose of bay leaf extract (T3) resulted in significantly lower LDL levels than both the lower dose groups (T1 and T2), with p-values of 0.018 and 0.013, respectively. This indicates a dose-dependent effect of bay leaf extract on LDL reduction. The T3 group also showed a significant difference in LDL levels compared to the positive control (PC) group treated with simvastatin, with a p-value of 0.019. This suggests that the highest dose of bay leaf extract had a comparable LDL-lowering effect to simvastatin. The results of the post hoc analysis support the hypothesis that increasing doses of bay leaf extract leads to a progressive reduction in LDL cholesterol levels. The highest dose of bay leaf extract (1.80 grams) was found to be the most effective in lowering LDL, exhibiting an effect comparable to that of simvastatin. These findings suggest the potential of bay leaf extract as a therapeutic agent for managing hypercholesterolemia.

Table 2. Post Hoc analysis (Mann-Whitney U test) results for LDL cholesterol levels.

Comparison	p-value
NC vs. T1	0.018
NC vs. T2	0.013
NC vs. T3	0.018
T1 vs. T3	0.018
T2 vs. T3	0.013
T3 vs. PC	0.019

*p<0.05.

The present study delved into the potential of bay leaf extract as a natural therapeutic agent for managing hypercholesterolemia, a condition characterized by elevated levels of low-density lipoprotein (LDL) cholesterol, a major risk factor for cardiovascular disease. The investigation focused on the dose-dependent effects of bay leaf extract on LDL cholesterol reduction in a rat model of hypercholesterolemia. The findings of the study provide compelling evidence that bay leaf extract can effectively lower LDL cholesterol levels in a manner that is directly proportional to the administered dose. The most significant reduction was observed with the highest dose of bay leaf extract (1.80 g), which demonstrated an efficacy comparable to that of simvastatin, a widely used lipid-lowering medication. These results highlight the promising potential of bay leaf extract as a therapeutic option for managing hypercholesterolemia and its associated cardiovascular risks. The study's success in inducing hypercholesterolemia in rats through a high-fat diet laid a solid foundation for evaluating the efficacy of bay leaf extract. The significant elevation of LDL cholesterol levels in the pre-treatment group, far exceeding the normal range, confirmed the establishment of a hypercholesterolemic state, providing a suitable model for assessing the therapeutic potential of the extract.[6-8]

The subsequent administration of bay leaf extract at varying doses revealed a clear dose-response relationship. As the dosage of the extract increased, a corresponding decrease in LDL cholesterol levels was observed. This observation suggests that the bioactive compounds within bay leaf extract exert their cholesterol-lowering effects in a concentration-dependent manner. The mechanism underlying this dose-dependent response could involve the inhibition of key enzymes involved in cholesterol biosynthesis or the modulation of cholesterol absorption and excretion pathways. The most striking finding of the study was the comparable efficacy of the highest dose of bay leaf extract (1.80 g) to simvastatin in reducing LDL cholesterol levels. Simvastatin, a member of the statin class of drugs, is a cornerstone of hypercholesterolemia management due to its potent inhibitory action on HMG-CoA reductase, a rate-limiting enzyme in cholesterol synthesis. The observation that bay leaf extract, a natural product, can achieve similar LDL-lowering effects as simvastatin underscores its potential as a safe and effective alternative or adjunct to conventional lipid-lowering medications.[7-9]

The potential therapeutic benefits of bay leaf extract can be attributed to its rich phytochemical composition, which includes flavonoids and tannins. Flavonoids, potent antioxidants, have been shown to inhibit HMG-CoA reductase, thereby reducing cholesterol production in the liver. Tannins, on the other hand, impede intestinal fat absorption by binding to dietary cholesterol, preventing its uptake into the bloodstream. The combined action of these and other bioactive compounds in bay leaf extract likely contributes to its observed cholesterol-lowering effects. The findings of this study have significant implications for the management of hypercholesterolemia and the prevention of cardiovascular disease. The dose-dependent response observed with bay leaf extract suggests that its

therapeutic efficacy can be optimized by adjusting the dosage. The comparable efficacy of the highest dose to simvastatin raises the possibility of using bay leaf extract as a natural alternative or adjunct to statin therapy, particularly for individuals who experience adverse effects or are intolerant to statins. Furthermore, the favorable safety profile of bay leaf extract, with few reported side effects, makes it an attractive option for long-term use. This is particularly important in the context of hypercholesterolemia management, which often requires chronic treatment to maintain optimal lipid levels and reduce cardiovascular risk. However, it is crucial to acknowledge that this study has certain limitations. The research was conducted in a preclinical rat model, and further investigations in human subjects are necessary to confirm the efficacy and safety of bay leaf extract in a clinical setting. Additionally, the precise mechanisms underlying the cholesterol-lowering effects of bay leaf extract warrant further exploration. Future studies should also investigate the potential synergistic effects of bay leaf extract with other natural products or conventional medications. The present study provides compelling evidence for the dose-dependent LDL cholesterol-lowering effects of bay leaf extract in a hypercholesterolemic rat model. The highest dose tested exhibited comparable efficacy to simvastatin, a standard lipid-lowering medication, suggesting the potential of bay leaf extract as a safe and effective therapeutic agent for managing hypercholesterolemia. These findings warrant further investigation in human subjects to explore the clinical implications of bay leaf extract in the prevention and treatment of cardiovascular disease.[9-11]

The observed reduction in LDL cholesterol levels following the administration of bay leaf extract can be attributed to the complex interplay of its bioactive constituents, primarily flavonoids and tannins. These compounds exert their cholesterol-lowering effects through distinct yet complementary mechanisms that target key aspects of cholesterol metabolism and absorption. Flavonoids, a diverse group of polyphenolic compounds abundant in bay leaves, have been extensively studied for their antioxidant and anti-inflammatory properties. In the context of cholesterol metabolism, flavonoids have demonstrated the ability to inhibit 3-hydroxy-3 methylglutaryl-coenzyme A (HMG-CoA) reductase, a critical enzyme in the mevalonate pathway responsible for cholesterol biosynthesis. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, a crucial intermediate in the synthesis of cholesterol and other isoprenoids. By inhibiting this rate-limiting enzyme, flavonoids effectively curtail the de novo production of cholesterol in the liver. This reduction in hepatic cholesterol synthesis subsequently leads to a decrease in the assembly and secretion of very low-density lipoproteins (VLDL), the precursors of LDL cholesterol. The inhibitory action of flavonoids on HMG-CoA reductase is believed to be mediated through multiple mechanisms. Flavonoids may compete with the natural substrate, HMG-CoA, for binding to the active site of the enzyme, thereby impeding its catalytic activity. Flavonoids may bind to an allosteric site on the enzyme, inducing a conformational change that reduces its affinity for the substrate or impairs its catalytic efficiency. Flavonoids may influence the expression of genes involved in cholesterol biosynthesis, including the gene encoding HMG-CoA reductase, leading to a decrease in enzyme levels and subsequent cholesterol production. The antioxidant properties of flavonoids may also contribute to their cholesterol-lowering effects. Oxidative stress plays a pivotal role in the development and progression of atherosclerosis, the underlying pathological process in cardiovascular disease. By scavenging free radicals and other reactive oxygen species, flavonoids mitigate oxidative damage to LDL cholesterol, thereby reducing its atherogenic potential.[11-13]

Tannins, another class of polyphenols found in bay leaves, exert their cholesterol-lowering effects primarily by interfering with intestinal fat absorption. Tannins possess a high affinity for lipids, including cholesterol, and readily form complexes with them. This complexation reduces the bioavailability of dietary cholesterol, preventing its absorption into the

bloodstream. The mechanism by which tannins impede intestinal fat absorption involves several key steps. Tannins bind to cholesterol molecules in the intestinal lumen, forming insoluble complexes. Tannins may also interfere with the formation of micelles, small aggregates of bile acids, and lipids that facilitate the absorption of cholesterol and other fats. The insoluble tannin-cholesterol complexes and the disruption of micelle formation collectively reduce the uptake of cholesterol by intestinal cells (enterocytes). The unabsorbed cholesterol is subsequently excreted in the feces, leading to a net reduction in cholesterol absorption. In addition to their direct effects on cholesterol absorption, tannins may also indirectly influence cholesterol metabolism by modulating gut microbiota composition. Emerging evidence suggests that gut microbiota plays a crucial role in regulating host lipid metabolism. Tannins, through their antimicrobial and prebiotic properties, may promote the growth of beneficial gut bacteria that contribute to cholesterol homeostasis.[13-15]

The combined action of flavonoids and tannins in bay leaf extract likely contributes to its potent cholesterol-lowering effects. While flavonoids primarily target hepatic cholesterol synthesis, tannins focus on reducing intestinal cholesterol absorption. This dual mechanism of action provides a comprehensive approach to managing hypercholesterolemia, addressing both endogenous production and exogenous intake of cholesterol. Further research is warranted to elucidate the precise mechanisms underlying the cholesterol-lowering effects of bay leaf extract and its individual components. In-depth investigations into the pharmacokinetics, pharmacodynamics, and potential synergistic interactions of flavonoids and tannins are crucial for optimizing their therapeutic application. Additionally, clinical trials are necessary to evaluate the efficacy and safety of bay leaf extract in human subjects with hypercholesterolemia. The observed LDL cholesterol reduction following bay leaf extract administration can be attributed to the synergistic effects of its bioactive constituents, primarily flavonoids, and tannins. Flavonoids inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis, while tannins impede intestinal fat absorption. This dual mechanism of action provides a promising avenue for developing natural, safe, and effective strategies for managing hypercholesterolemia and reducing cardiovascular disease risk.[14-16]

The dose-dependent response observed in this study underscores a fundamental principle in pharmacology: the relationship between drug dosage and its therapeutic effect. In the context of bay leaf extract, the findings highlight that the magnitude of LDL cholesterol reduction is directly proportional to the administered dose, at least within the range tested in this study. This observation has significant implications for optimizing the therapeutic use of bay leaf extract in managing hypercholesterolemia. The fact that lower doses of bay leaf extract (0.72 g and 1.08 g) also demonstrated LDL-lowering effects, albeit to a lesser extent than the highest dose (1.80 g), suggests that even modest amounts of the extract can exert beneficial effects on lipid metabolism. This is encouraging, as it implies that individuals with mild hypercholesterolemia or those seeking preventive measures may benefit from incorporating bay leaf extract into their dietary regimen, even at lower doses. However, the observation that the highest dose (1.80 g) proved to be the most effective in reducing LDL cholesterol suggests that there is a threshold or saturation point beyond which further dose escalation may not yield additional benefits. This phenomenon is commonly observed with many drugs and natural products, where the therapeutic effect plateaus after reaching a certain dose. The reasons for this saturation point are multifaceted and may involve factors such as receptor saturation, limited bioavailability, or metabolic constraints.[15-17]

In the case of bay leaf extract, the saturation point may be related to the limited capacity of its bioactive constituents, such as flavonoids and tannins, to exert their cholesterol-lowering effects. Flavonoids, for instance, inhibit HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. However, once all available

enzyme molecules are bound and inhibited by flavonoids, further increases in flavonoid concentration may not lead to additional cholesterol reduction. Similarly, tannins impede intestinal fat absorption by binding to dietary cholesterol. However, there may be a limit to the amount of cholesterol that tannins can bind, beyond which further increases in tannin concentration may not significantly impact cholesterol absorption. The identification of a saturation point for the LDL-lowering effects of bay leaf extract has important practical implications. It suggests that there is an optimal dose that maximizes therapeutic benefit while minimizing the risk of potential adverse effects or unnecessary consumption of the extract. Exceeding this optimal dose may not only be futile in terms of further LDL reduction but may also increase the likelihood of encountering undesirable side effects, although bay leaf extract is generally considered safe. Therefore, the findings of this study emphasize the importance of careful dose optimization when utilizing bay leaf extract for therapeutic purposes. While lower doses may offer some benefits, the highest dose tested (1.80 g) appears to be the most effective in achieving significant LDL cholesterol reduction. However, it is crucial to conduct further research to determine the precise optimal dose in humans, considering factors such as individual variability, comorbidities, and potential drug interactions. Moreover, the identification of a saturation point underscores the need for a personalized approach to bay leaf extract therapy. The optimal dose may vary depending on the individual's baseline cholesterol levels, desired therapeutic goals, and tolerance to the extract. Healthcare professionals should carefully assess each patient's needs and tailor the dosage accordingly to ensure maximal efficacy and safety. The dose-dependent response observed in this study highlights the importance of optimizing the dosage of bay leaf extract for achieving maximal therapeutic benefit in managing hypercholesterolemia. While lower doses may offer some benefits, the highest dose tested (1.80 g) appears to be the most effective. However, further research is needed to determine the precise optimal dose in humans and to develop personalized treatment plans that maximize efficacy and safety.[18-20]

4. Conclusion

This study provides evidence for the dose-dependent LDL cholesterol-lowering effects of bay leaf extract in a hypercholesterolemic rat model. The highest dose (1.80 g) exhibited comparable efficacy to simvastatin, suggesting its potential as a therapeutic agent for managing hypercholesterolemia. Further research is warranted to explore the underlying mechanisms and clinical implications of these findings.

5. References

1. Anggelina B, Kristina SA, Wiedyaningsih C. Knowledge of cardiovascular disease and its association among the general population in Indonesia. J Manag Pharm Pract. 2023; 12(4): 234.
2. Luo Y, Liu J, Zeng J, Pan H. Global burden of cardiovascular diseases attributed to low physical activity: an analysis of 204 countries and territories between 1990 and 2019. Am J Prev Cardiol. 2024; 17: 100633.
3. Rethemiotaki I. Global prevalence of cardiovascular diseases by gender and age during 2010–2019. Arch Med Sci – Atheroscler Dis. 2024; 8(1): 196-205.
4. Erwin, Rizka Y, Kurniawan D. Risk factors of cardiovascular diseases on patients with cardiovascular diseases. KnE Medicine. 2023; 3(1): 76-83
5. Lee Y, Siddiqui W. Cholesterol Levels. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023.
6. Maharani A, Sujarwoto, Praveen D, Oceandy D, Tampubolon G, Patel A. Cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in Indonesia: The SMARThealth Extend study. PLoS One. 2019; 14(4): 1-13.

7. Sharmin F, Koyama T, Koyama H, Ishizaki S. Cholesterol-binding ability of saponin from Japanese starfish. J Food Sci Technol. 2021; 58(8): 3056-64.
8. Somalinggi YL, Maloa BR, Lau O, Putra TJ, Virginia DM. The effectiveness of bay leaf extract (*Syzygium polyanthum*) in overcoming gout in Indonesia. Pharm J. 2023; 19(2): 221-9
9. Talreja O, Kerndt CC, Cassagnol M. Simvastatin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024.
10. Ward NC, Watts GF, Eckel RH. Statin toxicity: mechanistic insights and clinical implications. Circ Res. 2019; 124(2): 328-50.
11. Li Y, Zhang T, Jiang Y. Hypocholesterolemic effects of dietary supplementation of bay leaf (*Syzygium polyanthum*) on high-cholesterol-fed rats. Food Sci Nutr. 2018; 6(1): 231-6.
12. Ranasinghe P, Jayawardana BC, Galappaththy P. Medicinal properties of 'true' cinnamon (*Cinnamomum zeylanicum*): a systematic review. BMC Complement Altern Med. 2013; 13: 275.
13. Prasad K, Laxdal VA. Reduction in hyperlipidemia and oxidative stress in hypercholesterolemic rats by a combination of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor and phenolic antioxidant. J Agric Food Chem. 2012; 60(10): 2657-63.
14. Fuhrman B, Volkova N, Coleman R. Dietary cholesterol, not saturated fat, is associated with high serum cholesterol in a multiethnic population. Nutr Metab Cardiovasc Dis. 2019; 29(10): 1038-46.
15. Mach F. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2017; 19(1): 5.
16. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA /AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73(24): e285-e350.
17. Catapano AL, Graham I, De Backer G. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37(39): 2999-3058.
18. Anderson TJ, Grégoire J, Hegele RA. 2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016; 32(11): 1263-82.
19. Lloyd-Jones DM, Morris PB, Ballantyne CM. 2017 ACC/AHA/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): e13-e115.
20. Piepoli MF, Hoes AW, Agewall S. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315-81.